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Abstract
Background: A significant number of smokers would like to stop smoking. Despite the demonstrated efficacy of
pharmacological smoking cessation treatments, many smokers are unwilling to use them; however, they are
inclined to try alternative methods. Hypnosis has a long-standing reputation in smoking cessation therapy, but its
efficacy has not been scientifically proven. We designed this randomised controlled trial to evaluate the effects of
group hypnosis as a method for smoking cessation, and we will compare the results of group hypnosis with group
relaxation.
Methods/Design: This is a randomised controlled trial (RCT) to compare the efficacy of a single session of
hypnosis with that of relaxation performed in groups of 8-15 smokers. We intend to include at least 220
participants in our trial. The inclusion criteria include smoking at least 5 cigarettes per day, not using other
cessation methods and being willing to quit smoking. The intervention is performed by a trained hypnotist/
relaxation therapist. Both groups first receive 40 min of mental preparation that is based on motivational
interviewing. Then, a state of deep relaxation is induced in the hypnosis condition, and superficial relaxation is
induced in the control condition. Suggestions are made in the hypnosis condition that aim to switch the mental
self-image of the participants from that of smokers to that of non-smokers. Each intervention lasts for 40 min. The
participants also complete questionnaires that assess their smoking status and symptoms of depression and anxiety
at baseline, 2 weeks and 6 months post-intervention. In addition, saliva samples are collected to assess cotinine
levels at baseline and at 6 months post-intervention. We also assess nicotine withdrawal symptoms at 2 weeks
post-intervention.
Discussion: To the best of our knowledge, this RCT is the first to test the efficacy of group hypnosis versus group
relaxation. Issues requiring discussion in the outcome paper include the lack of standardisation of hypnotic
interventions in smoking cessation, the debriefing of the participants, the effects of group dynamics and the
reasons for dropouts.
Trial registration: Current Controlled Trials, ISRCTN72839675.
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Background
In 2010, 19% of the Swiss population between 14 and 65
years of age were daily smokers, and the average smoker
smoked 14.2 cigarettes each day [1]. Although Switzer-
land ranks low in smoking prevalence in the European
Union, it still ranks higher than the UK, Sweden, Portu-
gal and the USA [2,3]. Smoking prevalence rates should
be compared with caution, however, due to the different
definitions of smoking and the various sampling meth-
ods [4]. Among daily and nondaily smokers in Switzer-
land, 26% have reported that they intend to quit
smoking within the following 6 months [1]. In addition,
other studies have reported a high willingness to quit
smoking and high rates of cessation attempts [5-8].
The use of nicotine replacement therapy (NRT) has
risen sharply in the past decade, and the efficacy of NRT
delivered as gum, patches, nasal sprays, inhalers or tablets
has been demonstrated [9,10]. Other pharmacological
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include the antidepressant bupropion and the nicotine
receptor partial agonist varenicline [11]. The adverse
effects of pharmacological cessation treatments are
usually mild to moderate [11], which makes them gener-
ally safe to use.
Studies have also shown that smokers have concerns
about pharmacological cessation methods, which makes
them hesitant to use pharmacological methods. One
study found that one-quarter of smokers worried about
t h ep o s s i b l es i d ee f f e c t so fN R T ,a n do n l y1 6 %a c t u a l l y
b e l i e v e dt h a tN R Tc o u l dh e l pt h e mq u i ts m o k i n g[ 1 2 ] .
Smokers’ worries about NRT might be influenced by
inaccurate statistical comparisons between the success
o fN R Ta n dt h em o r ec o m m o n l yu s e d“cold turkey”
method. In addition, smokers tend to have a mispercep-
tion of nicotine withdrawal symptoms as NRT side
effects and false beliefs that nicotine is a major cause of
tobacco-related health problems [13]. Nevertheless,
these prior studies have indicated that not all smokers
are willing to use pharmacological cessation methods to
quit smoking. As a result, a vast spectrum of non-phar-
macological methods has become available, ranging
from self-help materials, counselling and advice on cog-
nitive-behavioural therapy to methods of alternative
medicine.
One form of alternative medicine that has been prac-
ticed for many years in smoking cessation is hypnosis
[14]. On the basis of the American Psychological Asso-
ciation’s Division 30 (Society of Psychological Hypnosis)
definition, hypnosis describes the procedure “in which
one person (the subject) is guided by another (the hyp-
notist) to respond to suggestions for changes in subjec-
tive experience, alterations in perception, sensation,
emotion, thought, or behavior... Details of hypnotic pro-
cedures and suggestions will differ depending on the
goals of the practitioner and the purposes of the clinical
or research endeavour. Procedures traditionally involve
suggestions to relax...” [15]. Different assumptions exist
regarding the mode of action of hypnosis in smoking
cessation. By acting on underlying impulses, hypnosis
may weaken the desire to smoke, strengthen the will to
stop or improve the ability to respond to a treatment
programme. The success of hypnotherapy may also criti-
cally depend on factors such as the hypnotisability of
subjects, nonspecific ceremonial, anticipatory and pla-
cebo factors or the relationship between the therapist
and the subject [16].
Smokers are aware of hypnosis as a method of smok-
ing cessation [17], and acceptance of this method
among smokers seems high. One study reported that
67% of tobacco users expressed an interest in the future
use of hypnosis for smoking cessation [18]. There is still
insufficient scientific evidence, however, for the efficacy
of hypnosis in smoking cessation, which is primarily due
to the large variation in control interventions and miss-
ing information about hypnotic interventions. Systematic
reviews repeatedly concluded that hypnotherapy has not
been proved to have any greater effect on 6 month ces-
sation rates compared with other interventions or no
intervention at all [14,19]. These reviews recommended
that large trials in which the type of hypnotherapy was
clearly defined and described were needed to establish
the efficacy of hypnosis in smoking cessation. In addi-
tion, comparisons should be made with active interven-
tions of equal duration.
Aims of the trial
The aim of the present trial is to investigate whether a
single session of hypnosis evokes biologically validated
higher rates of smoking abstinence than a single session
of relaxation 2 weeks and 6 months following the inter-
vention (primary outcome). Our trial is designed to com-
ply with the recommendations that were presented in the
systematic reviews of hypnotherapy in smoking cessation
[14,19]. The hypnosis and relaxation sessions are per-
formed in a single-session group format to evaluate them
as economically feasible and time-efficient alternatives to
existing methods of smoking cessation. To the best of
our knowledge, this is the first randomised controlled
trial (RCT) that investigates the effectiveness of group
hypnosis. Secondary outcomes include nicotine withdra-
wal symptoms, smoking abstinence self-efficacy and
symptoms of depression and anxiety. In this trial, we
further aim to compare the cessation rates observed in
our study with cessation rates following established and
proven cessation treatments reported in other studies.
Methods/Design
Recruitment and randomisation
Recruitment is initiated through online and print adver-
tisements. Upon first contact via e-mail or telephone,
the prospective participants are asked to complete a
form showing possible dates for the group hypnosis or
relaxation (therapy) session. A therapy session is orga-
nised when 8 to 15 participants have signed up for the
same date, and the participants are informed about the
date and location of their session. Further study infor-
mation is provided to the participants in advance, either
in the context of a short informational meeting or
through written materials. The participants are provided
with the following information prior to the therapy
session:
- No clear results exist regarding the efficacy of group
hypnosis and relaxation in smoking cessation
- It is unclear which method is more successful
- Each participant has a 50% chance of being assigned
to the hypnosis or relaxation condition
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The participants are assigned to the hypnosis or the
relaxation group condition using an online randomisa-
tion program and remain unaware of their assignment
until the end of the therapy session. The therapist is
blind with regard to the respective condition until the
conclusion of the first part of the intervention.
Participants
Men and women are eligible to participate in the study
if they smoke at least 5 cigarettes per day, are willing to
quit smoking and are not currently using other methods
of smoking cessation (see the overview in Table 1). The
participants should understand and speak German, be
between 18 and 65 years of age, not be intoxicated by
alcohol or other substances (except for nicotine) before
and during the intervention, not have a history of psy-
chotic disorders and should not use stimulating medica-
tions (e.g., venlafaxine or methylphenidate). To ensure
their commitment to smoking cessation and their moti-
vation for the hypnosis or relaxation intervention, the
participants contribute 40 Swiss Francs (ca. 37 USD) for
their participation.
Setting
T h ep r e s e n ts t u d yi su n d e r t a k e nb yt h eS w i s sI n s t i t u t e
for Research in Public Health and Addictions (RIPA),
which is associated with the University of Zurich. The
therapy sessions take place in the conference rooms of
hotels or the institutions involved, either in Zurich city
or in a small town in Northwest Switzerland between 8-
10 pm on weekdays and between 10-12 am on Satur-
days. At the beginning of each session, the participants
are welcomed by the project leader (first author), asked
to turn off their mobile phones devices and instructed
to complete the informed consent. The inclusion and
exclusion criteria are provided in Table 1. Following
detailed instructions, the participants are asked to use a
saliva-measuring device and to complete a number of
questionnaires. Then, the therapist is introduced to the
participants, and the session begins. The therapist is a
trained hypnotist and relaxation therapist with a private
practice independent from RIPA. The follow-up assess-
ments include a detailed telephone interview 2 weeks
(t1) post-intervention by a trained scientific employee of
RIPA and a postal assessment 6 months (t2) post-inter-
vention (please see the trial flowchart in Figure 1).
Measurement instruments
The primary outcome is the biological validation of a 30
day point prevalence of nicotine abstinence [20]. The fol-
lowing secondary outcome instruments are used to assess
nicotine withdrawal symptoms, smoking abstinence self-
efficacy and symptoms of depression and anxiety: the
Minnesota Nicotine Withdrawal Scale (MNWS) [21]; the
smoking abstinence self-efficacy assessment [22], short
version translated into German [23]; the short version of
the Beck Depression Inventory (BDI-V) [24], which is a
derived, validated, and user-friendly German short ver-
sion of the classical Beck Depression Inventory [25]; and
the Beck Anxiety Inventory (BAI) [26], which was trans-
lated into German and validated [27].
At baseline, sociodemographic data about the partici-
pants (e.g., age, education, and nationality) and smok-
ing-related variables (number and nature of previous
cessation attempts, age at first cigarette, smoking rela-
tives etc.) are collected. The following baseline instru-
ments are also assessed: the Fagerström Test for
Nicotine Dependence [28], which was translated into
German and validated [29]; the “Fragebogen Substanza-
namnese” (FDA), which ascertains the lifetime con-
sumption, the past month’s consumption and the
manner of consumption for the DSM-IV/ICD-10 sub-
stances of abuse (this measure was derived from the
EuropeASI) [30]; the Health Survey SF-12 [3], which
was translated into German [31]; and the body mass
index (BMI). A detailed overview of the intake and out-
come assessments used during the course of the study is
provided in Table 2.
Table 1 Inclusion and exclusion criteria and reasoning
Inclusion Criteria Reasoning
- Minimum age of 18 years, maximum age of 65 To ensure a minimum age of participation
- Smoking an average of at least 5 cigarettes per day To ensure inclusion of regular smokers only
- Provision of informed consent To ensure informed consent of the subjects
Exclusion Criteria Reasoning
- Participation in other psychosocial or pharmacological interventions/therapies
that could interfere with smoking cessation or any NRT treatments or
medications for smoking cessation during the study
To avoid confounding treatment effects
- Acute alcohol or other substance use intoxication other than nicotine To avoid confounding of alcohol or substance use effects
- Any signs of psychotic symptoms To avoid subjects with these problems entering the study as
symptoms could be exacerbated during relaxation or hypnosis
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To ensure validation of the primary outcome, biological
validation is provided by salivary cotinine measure-
ments. The concentration of cotinine, which is a meta-
bolite of nicotine, is assed via liquid chromatography-
mass spectrometry/mass spectrometry (LC-MS/MS)
analysis at the Institute of Forensic Medicine of the Uni-
versity of Zurich.
Sample collection and cotinine determination
The saliva samples are collected using Quantisal
® saliva
collection devices (nal von minden, Regensburg, Ger-
many). A basic liquid-liquid extraction is employed
using cotinine-d3 (c = 0.05 ng/μL) as an internal stan-
dard. The dried extracts are reconstituted in 100 μLo f
water containing ammonium formate. The sample is
transferred to an autosampler vial, and 10 μL of sample
Figure 1 Trial flowchart. This figure provides an overview of the procedures for the participants.
Table 2 Measurements and instruments
Variable Intake assessment (t0) Two week follow-up
(t1) - telephone interview
Six month follow-up (t2) -
postal assessment
Sociodemographic
information
Age, education, civil status
Tobacco and other
substance consumption
Fagerström Test for Nicotine Dependence FTND
[28], German translation [29];
smoking abstinence
self-efficacy [22],
short version and
German translation [23];
history of tobacco use
and tobacco cessation attempts; history of
substance use (FDA);
Smoking friends and relatives;
Age at first cigarette;
Previous cessation attempts (number and
nature);
Body Mass Index
Minnesota Nicotine Withdrawal Scale
MNWS [21];
smoking abstinence
self-efficacy; point prevalence of
tobacco abstinence (last 7 days)
Point prevalence of tobacco
abstinence
(last 30 days)
Mental health status Beck Depression Inventory [25]; BDI-V, short
version and German translation [24];
Beck Anxiety Inventory (BAI) [26], German
translation [27]
BDI-V, BAI BDI-V, BAI
General health status SF-12 [3], German translation [31] -
Safety - Adverse events Adverse events
Biological assessments Salivary cotinine measurement - Salivary cotinine
measurement
Misc. assessments - Use of CD Use of CD
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separated using a Shimadzu integrated high-pressure
liquid chromatography (HPLC) system followed by MS/
MS detection using an AB Sciex 5500 Q Trap linear ion
trap quadrupole mass spectrometer with Analyst soft-
ware (AB Sciex, Darmstadt, Germany). Gradient elution
is performed on a reversed-phase column (Synergi 4 μ
POLAR-RP 80A, Phenomenex, Aschaffenburg, Ger-
many). The mobile phase consists of 5 mM ammonium
formate buffer, which is adjusted to pH 3.5 with formic
acid (eluent A), and methanol containing ammonium
formate (eluent B). The column oven is set at 40°C.
Transitions for multiple-reaction monitoring (MRM) are
selected, and their setting parameters are determined
using Analyst Software in quantitative optimisation
mode. The mass spectrometer is operated in the infor-
mation-dependent acquisition mode. The MRM mode is
used for the survey scan, and this is followed by the
dependent scan, which is an enhanced product ion scan
(EPI). Unambiguous identification is achieved by com-
paring the resulting EPI mass spectra with reference
spectra from an in-house library. The three selected
MRM transitions for cotinine are 177/80, 177/98 and
177/53, and the selected MRM transitions for cotinine-
d3 are 180/80 and 180/53.
Quantitative analysis and cut-off
Calibration curves are prepared with cotinine-free saliva
and buffer spiked with cotinine and IS in the following
cotinine concentrations (ng/mL saliva): 1 ng/mL, 2 ng/
mL, 4 ng/mL, 20 ng/mL, 40 ng/mL, 80 ng/mL, 400 ng/
mL and 800 ng/mL. A calibration range of 1 to 80 ng/
mL is used for low cotinine concentrations, whereas a
r a n g eo f8 0t o8 0 0n g / m Li su s e df o rh i g hc o n c e n t r a -
tions. A spiked quality control containing 8 ng/mL coti-
nine is used in addition to an authentic sample with a
known concentration of the analytes. To differentiate
between active nicotine consumption and passive non-
consumption, a cut-off value of 5 ng/mL saliva is used.
Handling of conflicting results and other problems
The participants whose saliva sample result is positive
even though they state that they did not smoke during
the follow-up period are asked for a second saliva sam-
ple. If the second saliva sample is also positive, then
they will count as smokers in the intention-to-treat ana-
lysis. In the case that the first saliva sample is invalid or
there is any suspicion of falsification, a second saliva
sample is collected. If the second sample is still unclear,
then the participant will count as a smoker.
The participants who provide informed consent for
t h es t u d yb u tr e f u s et op r o v i d eas a l i v as a m p l ew i l l
count as smokers. In addition, they are offered the
option of having their partner or someone in close con-
tact with them confirm their smoking status. Although
the confirmations of close family members or friends
have been shown to be reliable [32], the participants
who do not provide a saliva sample will not be included
in the primary outcome analyses (i.e., their results will
be reported separately).
Estimation of effect size
For the estimation of effect size, we refer to a study of
Carmody et al. [33] that investigated the efficacy of hyp-
nosis versus behavioural individualised counselling com-
bined with nicotine patches. They recruited a total of
286 subjects, many of whom were war veterans. The
interventions in the Carmody et al. study resulted in 30
day point prevalences of smoking abstinence of 26% in
the intervention group and 18% in the control group.
Although the Carmody et al. study conducted individual
interventions, we aim to recruit motivated subjects and
conduct group interventions. In the present study, we
expect abstinence rates of approximately 30% in the
hypnosis and 18% in the relaxation group condition.
Aiming for a statistical power of 80% and accepting an
alpha level of 5%, the target sample size for the current
trial is 156 individuals. Assuming a dropout rate of 40%,
we aim to include 220 participants.
Interventions
The interventions are divided into three parts. The first
part consists of psycho-education regarding smoking
cessation and is based on the principles of motivational
interviewing [34,35]. The participants’ intentions to quit
are reinforced through illustrative examples of the finan-
cial benefits of not smoking, smoking as a habit rather
than an addiction, and the importance of attitude and
commitment in smoking cessation. The participants are
prepared for situations in their everyday life that will
require enhanced attention and resistance, and they are
educated about ways to deal with these situations. A
flipchart is used to visualise important points. To rein-
force change, the participants are designated by the
therapist as non-smokers from the beginning of the ses-
sion. After a short break during which the participants
pay their contribution and the therapist is informed of
the respective intervention, the second part of the ses-
sion takes place with dimmed lights and soft back-
ground music.
The actual intervention occurs during the second part
of the therapy session. In the hypnosis condition, a light
hypnosis is induced through repetitive statements such
as “you are going deeper and deeper into relaxation” or
“you are very relaxed”. The induction of hypnosis
requires 4-5 min before the first set of suggestions is
made to disconnect pleasant experiences, such as socia-
lising or holidays, from the act of smoking. Hypnosis is
then deepened by repeating statements involving relaxa-
tion and by associating (’anchoring’)t h er e s u l t i n gs t a t e
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repeated to maintain this state. During deep relaxation,
the participants are given suggestions to switch their
self-image from that of smokers to non-smokers. In
addition, suggestions are made for the participants to
use their power to resist smoking in tempting situations
a n dt od e a lw i t hs y m p t o m ss u c ha sm o o ds w i n g so r
enhanced appetite, which may result as a consequence
of smoking cessation [36-38]. At the end of the session,
the participants are led back to full awareness.
In the relaxation condition, the participants are initi-
ally invited to make themselves comfortable and to
relax. No repetitive statements are made, and no
anchors are used to reinforce and deepen relaxation.
The participants are asked to listen to the music for 4-5
min before the same suggestive sentences used in the
hypnosis group are given; however, the participants in
the relaxation group are not in a mental and physical
state of hypnosis. The relaxation intervention lasts for
the same amount of time as the hypnosis intervention
(40 min).
In the third part of the intervention, the participants
are debriefed about the study condition and given a CD
for self-relaxation or self-hypnosis to repeat the poten-
tial effects of the intervention as frequently as they
desire. On the CDs for each group, the trained hypno-
tist/relaxation therapist speaks to relaxing background
music. In the self-hypnosis CD, the anchor is used to
r e p e a tt h es u g g e s t i o n st h a ta r em a d ed u r i n gt h eg r o u p
hypnosis. In the relaxation CD, corresponding sentences
are repeated without anchoring and without being
shifted to a mental and physical state of hypnosis. At
the end of the session, any open questions are answered.
Safety
During the 6 months duration of the study, the partici-
pants are offered the option of contacting the study
team in case they experience any adverse events. In the
introduction to the interventions, the participants are
instructed to go to the nearest hospital and/or call an
ambulance in case of unexpected emergencies. More-
over, adverse events are assessed systematically in the
follow-ups at t1 and t2 to avoid under-reporting of
adverse events (Figure 1).
Data analysis
T h ed a t aw i l lb ea n a l y s e da c c o r d i n gt ot h ei n t e n t i o n - t o -
treat principle. Intake measurements will be compared
using t tests and chi-square tests. Differences between
primary and secondary outcome variables at intake and
6 weeks will be tested using the generalised estimating
equation (GEE) algorithms within the statistical package
STATA 10 SE (StataCorp LP, College Station, Texas,
USA). Effect sizes and risk ratios will be calculated for
primary and secondary outcomes where appropriate.
Explorative predictor and moderator analyses on pri-
mary outcomes will be performed according to Kraemer
et al. [39]. In addition, we will conduct exploratory
regression analyses to test whether intake variables pre-
dict nicotine abstinence, smoking abstinence self-efficacy
and nicotine withdrawal (MNWS). For these analyses,
we will use linear, multinomial, or binary regression
models depending on the scale level of the outcome
measures.
Handling of study dropouts
Subjects that withdraw their informed consent or are
not available for the follow-up assessments at t1 and t2
will count as dropouts. Reasons for dropping out in the
participants who withdraw from informed consent are
assessed as soon as possible by a telephone interview
and will be reported systematically in the study dissemi-
nation process.
Ethical review
This RCT is executed in compliance with the Declara-
tion of Helsinki and has been reviewed by the Ethics
Committee of the Canton of Zurich, which did not
declare any objections (KEK-StV-Nr.16/10).
Discussion
To the best of our knowledge, this RCT is the first study
to test the efficacy of group hypnosis versus group
relaxation. It is also be the first study to explore the effi-
cacy of group hypnosis to reduce nicotine withdrawal
symptoms, symptoms of depression and anxiety that
potentially occur during smoking cessation and whether
smoking abstinence self-efficacy can be increased by
hypnosis. Moreover, predictor and moderator analyses
of primary outcomes will be performed.
There are some potential limitations regarding the
present study that will merit discussion in the main
report. First, we attempted to design our study in a
manner that would allow it to be comparable to other
studies of hypnotherapy and smoking cessation. For
example, we followed the recommendations of Barnes et
al. and Abbot et al. [14,19] when designing the study;
however, no standardised protocol exists for hypnotic
interventions in smoking cessation. There are some ele-
ments that are common to most interventions, such as
those named by Spiegel (e.g., that a body is entitled to
protection from smoke) [40], but there are many
degrees of freedom in the implementation of hypnotic
procedures that may affect the outcomes. The definition
of hypnosis suggested by APA Division 30 confirms the
relatively large scope regarding the induction and execu-
tion of hypnosis. Furthermore, it is plausible that the
nonspecific factors mentioned by Spiegel [16] may
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such nonspecific factors complicate comparisons
between studies. To approach the problem of non-stan-
dardisation, we will provide more details on the nonspe-
cific factors and on the precise execution of the
interventions (e.g., the wording of suggestions) in our
main study report.
Another potential concern is that the participants are
told about their study condition during the debriefing,
and some may even realise it by themselves during the
intervention. In the case that a participant prefers one
condition to the other, they might be disappointed, and
this could lower their motivation to resist smoking after
the session. Various considerations, however, led us to
the decision to reveal the study conditions to the parti-
cipants. We want to prevent any uncontrollable effects
of speculations, insecurities or convictions by the parti-
cipants regarding their study condition from mixing
with the effects of the interventions on the outcome
variables. Moreover, our intent is to evaluate group hyp-
nosis and relaxation as regular treatments to be offered
to the public and integrated into the healthcare system,
and patients would be aware of their treatment in the
real-world implementation of hypnosis and relaxation as
smoking cessation treatments. This point actually makes
our disclosure a strength of the study.
Group interventions might be influenced by group
dynamics, which could potentially affect a participant’s
experience of the intervention and its outcome. Single
individuals, for example, may dominate the group
through sarcastic remarks or other behaviours. We are
taking qualitative records of such group dynamics as
they occur, and we plan to include them in our data
interpretation as much as possible. The fact that the
participants may have attended alone or in the company
of an acquaintance also represents a variable in our data
collection system.
After the therapy session, we advise our study partici-
pants not to use any other smoking cessation methods
during the next 6 months to avoid confounding factors
of other interventions. As we have no possible way to
control the participants’ behaviours during this period,
we have to rely on self-reports about their use of other
smoking cessation therapies. Throughout the recruit-
ment, the therapy sessions and the follow-ups, however,
we emphasise to our participants that their honest infor-
mation is crucial to our study results and to the current
state of knowledge in science. In addition, we tell them
that there will not be any consequences if they report
trying out other methods. We hope that by conveying
this message to our participants, they are motivated to
cooperate throughout the study and provide us with
honest reports about their experiences after their ther-
apy session.
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